"10.1371_journal.pone.0054417","plos one","2013-01-22T00:00:00Z","Kristin I Løken-Amsrud; Kjell-Morten Myhr; Søren J Bakke; Antonie G Beiske; Kristian S Bjerve; Bård T Bjørnarå; Harald Hovdal; Finn Lilleås; Rune Midgard; Tom Pedersen; Jūratė Šaltytė Benth; Øivind Torkildsen; Stig Wergeland; Trygve Holmøy","Department of Neurology, Innlandet Hospital Trust, Lillehammer, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Norwegian Multiple Sclerosis Competence Centre, Department of Neurology, Haukeland University Hospital, Bergen, Norway; Department of Clinical Medicine, University of Bergen, Bergen, Norway; Kristian Gerhard Jebsen Multiple Sclerosis Research Centre, University of Bergen, Bergen, Norway; Department of Neuroradiology, Oslo University Hospital, Oslo, Norway; Multiple Sclerosis Centre Hakadal, Hakadal, Norway; Department of Medical Biochemistry, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway; Department of Laboratory Medicine, Childrens and Womens Health, Norwegian University of Science and Technology, Trondheim, Norway; Helsehuset Kongsberg, Kongsberg, Norway; Department of Neurology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway; Curato Oslo, Oslo, Norway; Department of Neurology, Molde Hospital, Molde, Norway; Unit for Applied Clinical Research, Norwegian University of Science and Technology, Trondheim, Norway; Unilabs Drammen, Drammen, Norway; Helse Sør-Øst Health Services Research Centre, Akershus University Hospital, Lørenskog, Norway; Department of Neurology, Akershus University Hospital, Lørenskog, Norway","Conceived and designed the experiments: KMM SJB AGB KSB BTB HH FL RM TP TH. Analyzed the data: KILA JSB TH. Contributed reagents/materials/analysis tools: KSB. Wrote the paper: KILA TH. Contributed by interpretation of the data and revising the manuscript: KMM SJB AGB KSB BTB HH FL RM TP ØT SW.","The study was partly supported by Merck-Serono, Pronova Biocare and Bayer Schering. Bård T. Bjørnarå is employed by Helsehuset Kongsberg, Finn Lilleås by Curato Oslo and Tom Pedersen by Unilabs. Kristin I. Løken-Amsrud has received travel support and an unrestricted research grant from Biogen Idec and travel support from Merck Serono. Kjell-Morten Myhr has received honoraria for lecturing, participation in pharmaceutical company sponsored clinical trials, and travel support from Bayer Schering, Biogen Idec, Novartis, Merck-Serono and Sanofi Aventis. Harald Hovdal has participated in pharmaceutical company sponsored clinical trials and received travel support from Merck Serono, Biogen Idec and Bayer Schering. Rune Midgard has received honoraria for lecturing, participation in pharmaceutical company sponsored clinical trials, and travel support from Bayer Schering, Biogen Idec, Novartis, Merck-Serono and Sanofi Aventis. Stig Wergeland has received speaker honoraria and travel support from Sanofi Aventis, Biogen Idec, Bayer Schering and Novartis. Trygve Holmøy has received speaker honoraria and travel support from Sanofi Aventis, Biogen Idec, Bayer Schering, Novartis and Merck Serono. There are no patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2013","01","Kristin I Løken-Amsrud","KILA",14,TRUE,10,NA,3,2,TRUE,TRUE,TRUE,1,"11",FALSE
